INTRODUCTION
============

Childhood cancer is defined as cancer occurring before 19 years of age. Although rare, it is the most common cause of death among children and adolescents, with approximately 300 000 new cases diagnosed each year worldwide \[[@b1-jpmph-52-4-205]\]. The burden of childhood cancer is mostly felt in low-income and middle-income countries, where the risk of mortality from childhood cancer is almost 4 times higher than in high-income countries \[[@b2-jpmph-52-4-205],[@b3-jpmph-52-4-205]\]. This is due to the low diagnostic rate, as patients usually do not seek treatment, and even those who do receive treatment often discontinue it due to an inability to afford the high costs of treatment. Moreover, the health professionals caring for such patients also lack specialized training \[[@b4-jpmph-52-4-205]\].

There are 12 different categories of childhood cancer according to the International Classification of Childhood Cancer, with the most common including leukaemia, lymphomas, brain tumours, and solid tumours \[[@b1-jpmph-52-4-205]\]. Although childhood cancer is mostly attributable to genetic and hereditary factors, environmental and lifestyle factors may also contribute to the occurrence of cancer among children and adolescents. However, in the majority of cases, the precise cause remains unknown. Studies on risk factors for childhood cancer have suggested that maternal reproductive factors are the major contributors, including a history of miscarriage, elderly primigravida status, and the intake of processed meats, alcohol, and tobacco. Paternal factors such as smoking and occupational exposure to hydrocarbons and paints have also been studied, but with unclear findings \[[@b5-jpmph-52-4-205],[@b6-jpmph-52-4-205]\].

Maternal vitamin consumption, especially folic acid supplementation during pregnancy, has consistently been shown to reduce the risk of neural tube defects \[[@b7-jpmph-52-4-205],[@b8-jpmph-52-4-205]\]. It may also reduce the risk of other congenital malformations such as cardiovascular defects \[[@b9-jpmph-52-4-205],[@b10-jpmph-52-4-205]\], oral clefts \[[@b11-jpmph-52-4-205],[@b12-jpmph-52-4-205]\], urinary tract defects \[[@b13-jpmph-52-4-205],[@b14-jpmph-52-4-205]\] and limb-reduction defects \[[@b10-jpmph-52-4-205],[@b12-jpmph-52-4-205]\]. Folic acid is the fully oxidized monoglutamyl form of folate, a water-soluble B vitamin \[[@b15-jpmph-52-4-205]\]. The World Health Organisation (WHO) has recommended daily supplementation with 400 μg of folic acid for women before and during pregnancy \[[@b16-jpmph-52-4-205]\]. A few studies have suggested that maternal supplementation of folic acid can prevent childhood cancers, such as acute lymphoblastic leukaemia (ALL) \[[@b17-jpmph-52-4-205],[@b18-jpmph-52-4-205]\], brain tumours \[[@b19-jpmph-52-4-205]\] and Wilms tumour \[[@b20-jpmph-52-4-205]\]. Hence, this systematic review aimed to determine the protective effects of maternal vitamin supplementation containing folic acid on childhood cancer, as a more thorough understanding of its protective effects will be important for future preventive strategies.

METHODS
=======

Search Protocol
---------------

Articles were searched systematically between September 1, 2018 and November 1, 2018, following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline. Four search engines---PubMed, Google Scholar, ProQuest, and Scopus---were utilised to search for articles. The search was carried out using keywords agreed upon in advance. The following keywords were derived from the PICO search guide: population (P): child\* OR infant\* OR adolescent\* OR "young people" OR paediatric OR "age 0 to 19 years old"; intervention (I): "maternal vitamin supplementation" OR "prenatal supplementation" OR "folate\* supplementation" OR "maternal medication"; comparison (C): compare all studies done in other countries; and outcome (O): cancer\* OR tumor\* OR neoplasms OR malignancy\* OR "acute lymphoblastic leukemia" OR lymphoma\* OR "acute myeloid leukemias" OR "central nervous neoplasms" OR "malignant bone tumors" OR neuroblastoma OR retinoblastoma OR "renal tumors."

Study Selection
---------------

Four reviewers were involved in this systematic review in order to have multiple rounds of relevance screening and to reduce bias \[[@b21-jpmph-52-4-205]\]. They were paired randomly as reviewer 1 (R1) and reviewer 2 (R2). In the first stage of the article search, 158 article titles and abstracts contained the search keywords. These article titles and abstracts were given to the paired reviewers at random. Each pair of reviewers received 79 article titles and abstracts to screen. The article titles and abstracts were reviewed by both reviewers, R1 and R2, and when there was disagreement, a third reviewer, R3, who was from another pair of reviewers, made a final determination of whether to accept or reject the article title or abstract. In total, 120 duplicates and irrelevant article titles and abstracts were removed at this stage. In the second stage of screening, 38 articles were retrieved for a full-text assessment. All 4 reviewers were given the retrieved articles to assess their relevance to the study. Finally, only 17 articles were found to be related to maternal supplementation with vitamins containing folic acid and childhood cancer ([Figure 1](#f1-jpmph-52-4-205){ref-type="fig"}). Data extraction was performed after a full review of the selected articles. The inclusion criteria were articles analysing the relationship of maternal folic acid supplementation during pregnancy with childhood cancer, case-control studies, original articles, articles written in English, and articles published after 1998. Unpublished studies, dissertations, reviews, studies investigating the maternal use of other vitamins and iron supplementation, and studies investigating the maternal use of medications for pain relief or medical conditions were excluded from the review.

Data Extraction and Data Synthesis
----------------------------------

A standardized form was used for data extraction from the studies that had been selected, including country, year published, study period, age of the children, the number of participants, the use of matching controls, matching variables, primary outcomes, and the quality of the study. All analyses were performed using Review Manager version 5.3 \[[@b22-jpmph-52-4-205]\]. The heterogeneity between studies in the meta-analysis was assessed using forest plots. The I^2^ and chi-square tests were used to formally check for the presence of heterogeneity. Heterogeneity was classified as low, medium and high for I^2^ values of 25%, 50%, and 75%, respectively, and for the chi-square test, a *p*-value \<0.05 was considered to indicate significance. The combined risk estimate was calculated using a random-effects model because the true effect size may not have been constant across all the included studies, and the effect measures were odds ratios (ORs).

Study Quality and Publication Bias
----------------------------------

The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the selected studies. The NOS evaluates 3 categories using 8 items to quantify study quality: selection of the participants, comparability of the participant group, and exposure ascertainment. A maximum of 1 star is given for each item within the selection and exposure categories, while a maximum of 2 stars can be given in the comparability category. The total maximum score of these 3 categories is 9. A study with a score of ≥7 was considered to be a high-quality study \[[@b23-jpmph-52-4-205]\]. Two authors independently assessed the quality of the selected studies. All potential confounders, such as the duration of folic acid consumption during pregnancy, dietary intake, and maternal medication history, were considered. Publication bias was evaluated using funnel plots, followed by the regression-based approach proposed by Egger et al. \[[@b24-jpmph-52-4-205]\] and the rank correlation test provided by Begg and Mazumdar \[[@b25-jpmph-52-4-205]\], which are formal and objective tests for publication bias.

Ethics Statement
----------------

This paper is a systematic review and meta-analysis study so it did not need ethical consideration.

RESULTS
=======

A summary of the selected studies is presented in [Table 1](#t1-jpmph-52-4-205){ref-type="table"}. All studies had a case-control design. Five studies reported findings for childhood ALL \[[@b18-jpmph-52-4-205],[@b26-jpmph-52-4-205]-[@b29-jpmph-52-4-205]\], 4 studies investigated both childhood ALL and acute myeloid leukaemia (AML) \[[@b30-jpmph-52-4-205]-[@b33-jpmph-52-4-205]\], 5 studies dealt with childhood brain tumours (CBT) \[[@b34-jpmph-52-4-205]-[@b38-jpmph-52-4-205]\], 1 study reported findings for both childhood ALL and lymphoma \[[@b39-jpmph-52-4-205]\], 1 study investigated germ cell tumours \[[@b40-jpmph-52-4-205]\] and 1 study reported findings for childhood ALL, AML, CBT, lymphoma, neuroblastoma, Wilms tumour, bone tumours, soft tissue sarcoma, and non-Hodgkin lymphoma \[[@b41-jpmph-52-4-205]\]. We only conducted a meta-analysis on childhood ALL, AML, and CBT. Childhood ALL and AML were analysed separately, as these diseases have different origins. As there was only 1 study that reported information regarding germ cell tumours, lymphoma, neuroblastoma, Wilms tumour, bone tumours, soft tissue sarcoma, and non-Hodgkin lymphoma, it was not possible to perform a meta-analysis for these tumours. However, the authors reported that maternal use of vitamins containing folic acid during pregnancy was associated with a reduction in the risk of germ cell tumours (OR, 0.7; 95% confidence interval \[CI\], 0.4 to 1.2) \[[@b40-jpmph-52-4-205]\] and non-Hodgkin lymphoma (OR, 0.68; 95% CI, 0.48 to 0.97) \[[@b41-jpmph-52-4-205]\].

Maternal folic acid supplementation was associated with a protective effect against childhood ALL (OR, 0.75; 95% CI, 0.66 to 0.86; *p*\<0.001) ([Figure 2A](#f2-jpmph-52-4-205){ref-type="fig"}). Maternal folic acid supplementation also showed a protective effect against childhood AML, but that effect was statistically insignificant (OR, 0.70; 95% CI, 0.46 to 1.06; *p*=0.10) ([Figure 2B](#f2-jpmph-52-4-205){ref-type="fig"}). No significant association was found between maternal folic acid supplementation and CBT (OR, 1.02; 95% CI, 0.88 to 1.19; *p*=0.78) ([Figure 2C](#f2-jpmph-52-4-205){ref-type="fig"}). There was moderate heterogeneity among all the studies. The studies' quality scores were high, ranging from 7 to 8. The quality scores of each study are summarized in [Table 1](#t1-jpmph-52-4-205){ref-type="table"}. No publication bias was detected in the childhood ALL studies (Egger test: *p*= 0.126; Begg rank correlation: *p*=0.161), childhood AML studies (Egger test: *p*=0.334; Begg rank correlation: *p*=0.462), or CBT studies (Egger test: *p*=0.290; Begg rank correlation: *p*= 0.707) ([Figure 3](#f3-jpmph-52-4-205){ref-type="fig"}).

DISCUSSION
==========

The WHO has recommended prophylactic folic acid supplementation of 300 μg/d since 1968 to prevent neural tube defects, and in 1998, the recommended amount increased to 400 μg daily during pregnancy \[[@b16-jpmph-52-4-205]\]. Folic acid supplementation should be started before conception to obtain an optimal preventive effect against neural tube defects and other congenital abnormalities \[[@b16-jpmph-52-4-205]\]. Apart from folic acid, maternal vitamins given routinely during pregnancy include iron, vitamin B12, and vitamin C, especially in developing countries \[[@b16-jpmph-52-4-205]\], and vitamin D in certain countries \[[@b42-jpmph-52-4-205]\].

The present systematic review revealed that maternal folic acid supplementation was associated with a protective effect against childhood ALL (OR,0.75; 95% CI, 0.66 to 0.86; *p*\<0.001). This finding is similar to that of a previous meta-analysis conducted in the USA in 2007 (OR, 0.64; 95% CI, 0.53 to 0.78) \[[@b43-jpmph-52-4-205]\]. However, Goh et al. \[[@b43-jpmph-52-4-205]\] did not specify which types of vitamins showed a protective effect against childhood cancer. Metayer et al. \[[@b44-jpmph-52-4-205]\] reported that maternal intake of both vitamins and folic acid at any time during pregnancy was associated with a reduced risk of ALL in the offspring, with ORs of 0.85 (95% CI, 0.78 to 0.92) and 0.80 (95% CI, 0.71 to 0.89), respectively. Metayer et al. \[[@b44-jpmph-52-4-205]\] conducted a study based on a large international collaboration, known as the Childhood Leukemia International Consortium Study (CLIC). The CLIC studies involved 10 countries with a total of 19 183 participants. The large sample sizes in the CLIC studies enabled the researchers to better determine the average values of their data and to minimise errors \[[@b45-jpmph-52-4-205],[@b46-jpmph-52-4-205]\].

For childhood AML, this systematic review revealed that maternal folate supplementation showed a protective effect against childhood AML, but without statistical significance (OR, 0.70; 95% CI, 0.46 to 1.06; *p*=0.10). The statistical insignificance of the association between maternal folate supplementation and AML most likely occurred because AML is a relatively rare disease compared to ALL among children \[[@b47-jpmph-52-4-205]\]. This finding is similar to that of Metayer et al. \[[@b44-jpmph-52-4-205]\], who reported no significant association between AML and maternal folic acid supplementation (OR, 0.92; 95% CI, 0.75 to 1.14).

In this study, there was no significant association between maternal folic acid supplementation and CBT (OR, 1.02; 95% CI, 0.88 to 1.19; *p*=0.78). This finding was different from the recently published meta-analysis by Chiavarini et al. \[[@b48-jpmph-52-4-205]\], who reported that maternal folic acid intake was inversely associated with the risk of childhood brain and spinal cord tumours (OR, 0.77; 95% CI, 0.67 to 0.88).

Apart from these protective effects, other studies have been conducted to evaluate the possible effects of folic acid supplementation on cancer risk. A meta-analysis of data from 50 000 subjects found that folic acid supplementation with a duration of 5 years showed no significant association with cancer (relative risk, 1.06; 95% CI, 0.99 to 1.13) compared to placebo \[[@b49-jpmph-52-4-205]\]. However, folic acid fortification programs implemented in Canada and USA have led to a reduction in the incidence of cancers such as Wilms tumour, neuroblastoma, and primitive neuroectodermal tumours among children according to ecological studies \[[@b20-jpmph-52-4-205]\].

The mechanism underlying this protective effect is still debated. Folic acid is essential for nucleotide synthesis \[[@b50-jpmph-52-4-205]\]. Therefore, folic acid deficiency causes chromosomal breaks due to the massive incorporation of uracil into human DNA. This mechanism is similar to that of DNA damage caused by radiation, which is likely a major cause of cancer in children, as well as in adults \[[@b51-jpmph-52-4-205]\]. Deficiencies of other micronutrients, such as vitamin B12, vitamin B6, niacin, vitamin C, vitamin E, iron, and zinc can also cause DNA damage due to DNA strand breaks and oxidative reactions \[[@b50-jpmph-52-4-205]\]. However, several animal studies have suggested that folic acid supplementation may stimulate DNA methylation, potentially playing a role in carcinogenesis \[[@b50-jpmph-52-4-205]\], which contradicts the findings of a protective effect in most epidemiological studies among humans \[[@b20-jpmph-52-4-205],[@b44-jpmph-52-4-205],[@b49-jpmph-52-4-205]\].

This meta-analysis has certain strengths and limitations. The strengths are that the search strategy used in this systematic review and meta-analysis was extensive, and that the articles were retrieved from 4 databases and no publication bias was noted. A limitation is that all studies included in this study had a case-cohort design, since limited cohort studies have investigated the association between folic acid and childhood cancers. Studies of correlations between maternal folic acid intake and childhood cancers have mostly been performed using case-control studies, most likely because case-control studies are relatively less costly and more suitable for rare diseases such as childhood cancers \[[@b52-jpmph-52-4-205]\].

In contrast to cohort studies, case-control studies create a hypothesis regarding the association between the exposure and disease or condition of interest, but do not provide evidence for a causal relationship \[[@b52-jpmph-52-4-205]\]. Furthermore, case-control studies are also associated with recall bias. As compared to controls, cases are likely to think harder in terms of recalling the exposure of interest \[[@b53-jpmph-52-4-205]\]. Maternal recall of folic acid use during specific periods of pregnancy may be subject to error. The effect estimates for folic acid supplementation used in this study might have been biased by exposure misclassification. Another disadvantage of case-control studies is the need to find an appropriate control group that does not have the disease or condition of interest, while still being similar to the case group with regard to other factors, such as age, race, and residential area \[[@b53-jpmph-52-4-205]\].

CONCLUSION
==========

Maternal intake of folic acid during pregnancy has a significant protective effect against childhood ALL. Mandatory prescriptions of folic acid for women during pregnancy, which have been implemented in most countries, are a good initiative that can prevent neural tube defects and reduce the risk of childhood cancer. Thus, we recommend that healthcare professionals provide regular health education and health promotion to raise awareness in the community regarding the benefits of taking folic acid during pregnancy.
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###### 

Summary of the reviewed articles

  Study                                                   Country                           Study period   Age of the children (y)   No. of participants                                                                                                      Matching control   Matching variables                                 Primary outcome                                         NOS score                                                                      
  ------------------------------------------------------- --------------------------------- -------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------ -------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------ ---
  Preston-Martin et al., 1998 \[[@b34-jpmph-52-4-205]\]   USA, France, Israel, and Europe   1976-1994      0-19                      1051                                                                                                                     1919               Varied by study centre                             Age, sex, geographic region                             CBT                                                                            8
  Wen et al., 2002 \[[@b26-jpmph-52-4-205]\]              USA and Canada                    1989-1993      \<15                      1842                                                                                                                     1986               Random-digit dialling                              Age, sex                                                ALL                                                                            8
  Shaw et al., 2004 \[[@b27-jpmph-52-4-205]\]             Canada                            1980-2000      \<15                      789                                                                                                                      789                Population-based registry                          Age, sex                                                ALL                                                                            7
  Ross et al., 2005 \[[@b30-jpmph-52-4-205]\]             North America                     1997-2002      \<20                      97 (ALL), 51 (AML)                                                                                                       173                Roster and birth registry                          Age, sex                                                ALL, AML                                                                       7
  Schüz et al., 2007 \[[@b41-jpmph-52-4-205]\]            Germany                           1992-1997      0-14                      650 (ALL), 105 (AML), 399 (CBT), 157 (neuroblastoma), 147 (Wilms tumour), 97 (bone tumours), 137 (soft tissue sarcoma)   2057               Population-based registry                          Sex, date of birth                                      ALL, AML, CBT, neuroblastoma, Wilms tumour, bone tumour, soft tissue sarcoma   7
  Johnson et al., 2009 \[[@b40-jpmph-52-4-205]\]          USA and Canada                    1993-2001      0-15                      278                                                                                                                      423                Random-digit dialling                              Birth year, sex                                         Germ cell tumours                                                              8
  Milne et al., 2010 \[[@b28-jpmph-52-4-205]\]            Australia                         2003-2007      0-15                      393                                                                                                                      1249               Random-digit dialling                              Age, sex, state of residence                            ALL                                                                            7
  Linabery et al., 2010 \[[@b31-jpmph-52-4-205]\]         USA                               1996-2006      \<1                       264 (ALL), 172 (AML)                                                                                                     324                State birth registry                               Birth year, location of residence                       ALL, AML                                                                       7
  Stålberg et al., 2010 \[[@b35-jpmph-52-4-205]\]         Sweden                            1990-1999      0-15                      512                                                                                                                      525                Medical birth register                             Location, sex, birth year                               CBT                                                                            7
  Ortega-García et al., 2010 \[[@b36-jpmph-52-4-205]\]    Spain                             2004-2006      0-15                      67                                                                                                                       155                Hospital record registry                           Birth year                                              CBT                                                                            8
  Amigou et al., 2012 \[[@b18-jpmph-52-4-205]\]           France                            2003-2004      0-15                      764                                                                                                                      1681               Population-based registry                          Age, sex, region                                        ALL                                                                            7
  Bailey et al., 2012 \[[@b29-jpmph-52-4-205]\]           Australia                         2003-2006      0-14                      333                                                                                                                      695                Random-digit dialling                              Age, sex, state of residence                            ALL                                                                            8
  Milne et al., 2012 \[[@b37-jpmph-52-4-205]\]            Australia                         2005-2011      0-14                      335                                                                                                                      1363               Random-digit dialling                              Age, sex, state of residence                            CBT                                                                            7
  Ajrouche et al., 2014 \[[@b32-jpmph-52-4-205]\]         France                            2010-2011      \<15                      636 (ALL), 100 (AML)                                                                                                     1421               Population-based registry, quota sampling method   Age, sex                                                ALL, AML                                                                       8
  Amitay et al., 2016 \[[@b39-jpmph-52-4-205]\]           Israel                            2005-2013      1-19                      121 (ALL), 69 (lymphoma)                                                                                                 384                Home communities                                   Age, sex                                                ALL, lymphoma                                                                  7
  Singer et al., 2016 \[[@b33-jpmph-52-4-205]\]           USA (California)                  1995-2008      0-14                      681 (ALL), 103 (AML)                                                                                                     1076               California birth certificates                      Date of birth, sex, Hispanic ethnicity, maternal race   ALL, AML                                                                       8
  Bailey et al., 2017 \[[@b38-jpmph-52-4-205]\]           France                            2010-2011      \<15                      301                                                                                                                      1421               Population-based registry                          Age, sex, region                                        CBT                                                                            8

NOS, Newcastle-Ottawa Scale; CBT, childhood brain tumour; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia.
